North America Colorectal Cancer Diagnostics Market Forecast to 2028
North America Colorectal Cancer Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Modality [Imaging Tests (Colonoscopy, CT Colonography, Flexible Sigmoidoscopy, Capsule Endoscopy, and Others) and Stool-Based Tests (Faecal Immunochemical Test (FIT), Guaiac-Based Faecal Occult Blood Test, and Stool DNA Test)] and End User (Hospitals, Diagnostic Laboratories, Cancer Research Institutes, and Others)
$2,100 – $3,500
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Launches of New Products Drive North America Colorectal Cancer Diagnostics Market
Major players in the colorectal cancer diagnostic market manufacture a wide range of devices that help reduce the burden of colorectal cancer and other associated indications such as colon polyps, Crohn’s disease, colitis, and irritable bowel syndrome. In July 2022, US Digestive Health (USDH), a network of top-rated gastrointestinal (GI) practices, announced the commercialization of AI-assisted colonoscopy screenings with the country’s largest installation of Genious Intelligent GI endoscopy modules. These modules are expected to help physicians identify hard-to-detect and potentially cancerous polyps in real time. With the launch of this device, patients throughout southeastern, southwestern, and central Pennsylvania can now access AI-assisted colonoscopy with enhanced capabilities. In September 2020, Olympus Corporation announced the launch of ENDO-AID, a cutting-edge platform powered by artificial intelligence (AI). The platform includes ENDO-AID CADe application (app), a computer-aided endoscopic method for the detection of different conditions of the colon. This new AI platform enables the real-time display of automatically detected suspicious lesions and works in combination with its EVIS X1. Thus, the frequent developments and new product launches drive the North America colorectal cancer diagnostics market growth.
North America Colorectal Cancer Diagnostics Market Overview
The North America colorectal cancer diagnostics market is segmented into the US, Canada, and Mexico. According to the American Society of Clinical Oncology, colorectal cancer is the third most common cancer diagnosed in men and women in the US. In 2023, an estimated 153,020 adults in the US will be diagnosed with colorectal cancer. These numbers include 106,970 new cases of colon cancer (54,420 men and 52,550 women) and 46,050 new cases of rectal cancer (27,440 men and 18,610 women). Further, ~1,880,725 people were diagnosed with colorectal cancer in 2020. Although older adults are more prone to colorectal cancer, the incidence of cancer is increasing among younger adults. The lifetime risk of getting affected by colorectal cancer is ~1 in 22 for men and ~1 in 24 for women. The American Society of Clinical Oncology (ASCO) estimated that ~52,550 deaths from colorectal cancer disease will occur in the US in 2023. In 2022, more than 600,000 surgeries were performed annually in the US to treat colon diseases. According to the American Cancer Society, the five-year survival rate for localized colon cancer is 91% and for localized rectal cancer is 90%. Overall, colorectal cancer mortality rates have been declined with better screening and treatment over the past 20 years. Moreover, screening reduces CRC mortality by decreasing incidences of CRC and increasing survival rates. The 2018 American Cancer Society CRC screening guideline recommends that adults aged 45 years and above must undergo regular screening with a high-sensitivity stool-based test or visual examination, depending on patient preference and test availability. In May 2021, the US Preventive Services Task Force changed its colorectal cancer screening recommendation. The age at which adults were at average risk of being diagnosed with colorectal cancer and recommended to begin screening was lowered from 50 to 45. Also, the government of the country supports research on colorectal cancer. The researchers worked to develop an advanced technique that can be used to prevent, detect, and treat colorectal cancer. The Colorectal Cancer Alliance is the world’s largest nonprofit colorectal cancer patient advocacy organization dedicated to funding colorectal cancer research. In 2020, an additional US$ 1.1 million in funding was made to support individual scientists through research grants. Thus, owing to abovementioned factors, the North America colorectal cancer diagnostics market is likely to propel during the forecast period.
North America Colorectal Cancer Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
North America Colorectal Cancer Diagnostics Market Segmentation
The North America colorectal cancer diagnostics market is segmented into modality, end user, and country.
Based on modality, the North America colorectal cancer diagnostics market is bifurcated into imaging tests and stool-based tests. In 2023, the imaging tests segment held a larger share of the North America colorectal cancer diagnostics market. The market for the imaging tests segment is further segmented into colonoscopy, CT colonography, flexible sigmoidoscopy, capsule endoscopy, and others. The market for the stool based tests segment is subsegmented into faecal immunochemical test (fit), guaiac-based faecal occult blood test (gFOBT), and stool DNA test.
Based on end user, the North America colorectal cancer diagnostics market is segmented into hospitals, diagnostic laboratories, cancer research institutes, and others. In 2023, the hospitals segment held the largest share of the North America colorectal cancer diagnostics market.
Based on country, the North America colorectal cancer diagnostics market is segmented into the US, Canada, and Mexico. In 2023, the US accounted for the largest share of the North America colorectal cancer diagnostics market.
Medtronic Plc; Illumina Inc; Clinical Genomics Technologies Pty Ltd; EDP Biotech Corp; Epigenomics AG; F. Hoffmann-La Roche Ltd; Quest Diagnostics Inc; Siemens Healthineers AG; Bruker Corp; and Eiken Chemical Co., Ltd. are among the leading companies operating in the North America colorectal cancer diagnostics market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Publishing status: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team’ research, the North America colorectal cancer diagnostic market was valued at US$ 4,315.86 million in 2023 and is expected to reach US$ 6,621.26 million by 2028, registering a CAGR of 8.9% from 2023 to 2028. Increasing prevalence of colorectal cancer and launches of new products are the critical factors attributed to the North America colorectal cancer diagnostic market expansion.
Colorectal cancer is a malignant tumor that develops in colonic or rectal tissues. It is the third most common type of cancer (excluding skin cancer) diagnosed yearly in the US. In 2021, 149,500 adults were diagnosed with colorectal cancer in the country. These numbers include 104,270 new colon cancer cases (52,590 men and 51,680 women) and 45,230 new rectal cancer cases (26,930 men and 18,300 women). During 2012–2016, the incidence of colorectal cancer rose by 2% in adults below 50 and 1% in adults of age 50–64 annually. It is estimated to be the fourth most diagnosed cancer among men and women of age 30–39 in the US. The disease caused 52,980 deaths (28,520 men and 24,460 women) in 2021. Surgery is the most common treatment for all stages of colon cancer. In ideal situations, if the cancer is diagnosed in the early stages, doctors can remove the tumor via surgical procedures. A colonoscopy is an important screening test for colorectal cancer diagnostics, and it has become a part of routine cancer screening. Thus, the rising incidence of colorectal cancer drives the growth of the North America colorectal cancer diagnostics market.
On the contrary, low accuracy of screening based on faecal immunochemical tests (FITs) hurdles the growth of North America colorectal cancer diagnostic market.
Based on modality, the North America colorectal cancer diagnostics market is bifurcated into imaging tests and stool based tests. The imaging tests segment held 94.0% share of North America colorectal cancer diagnostic market in 2023, amassing US$ 4,058.98 million. It is projected to garner US$ 6,248.43 million by 2028 to expand at 9.0% CAGR during 2023–2028. The market for the imaging tests segment is further segmented into colonoscopy, CT colonography, flexible sigmoidoscopy, capsule endoscopy, and others. The market for the stool based tests segment is subsegmented into faecal immunochemical test (fit), guaiac-based faecal occult blood test (gFOBT), and stool DNA test.
Based on end user, the North America colorectal cancer diagnostics market is segmented into hospitals, diagnostic laboratories, cancer research institutes, and others. The hospitals segment held 42.2% share of North America colorectal cancer diagnostic market in 2023, amassing US$ 1,820.01 million. It is projected to garner US$ 2,863.06 million by 2028 to expand at 9.5% CAGR during 2023–2028.
Based on country, the North America colorectal cancer diagnostic market is segmented into the U.S., Canada, and Mexico. Our regional analysis states that the US captured 78.6% share of North America colorectal cancer diagnostic market in 2023. It was assessed at US$ 3,392.22 million in 2023 and is likely to hit US$ 5,238.06 million by 2028, exhibiting a CAGR of 12.9% during the forecast period.
Key players profiles in the North America colorectal cancer diagnostic market report Medtronic Plc; Illumina Inc; Clinical Genomics Technologies Pty Ltd; EDP Biotech Corp; Epigenomics AG; F. Hoffmann-La Roche Ltd; Quest Diagnostics Inc; Siemens Healthineers AG; Bruker Corp; and Eiken Chemical Co., Ltd., among others.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America colorectal cancer diagnostics market.
o Highlights key business priorities in order to assist companies to realign their business strategies
o The key findings and recommendations highlight crucial progressive industry trends in the North America colorectal cancer diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the colorectal cancer diagnostics market, as well as those hindering it
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Research Team Report Guidance
1.3 Market Segmentation
1.3.1 North America Colorectal Cancer Diagnostics Market – by Modality
1.3.2 North America Colorectal Cancer Diagnostics Market – by End User
1.3.3 North America Colorectal Cancer Diagnostics Market – by Country
2. North America Colorectal Cancer Diagnostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Colorectal Cancer Diagnostics Market – Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Expert’s Opinion
5. North America Colorectal Cancer Diagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Colorectal Cancer
5.1.2 Launches of New Products
5.2 Key Restraints
5.2.1 Low Accuracy of Screening Based on Faecal Immunochemical Tests (FITs)
5.3 Opportunities
5.3.1 Growing Awareness of Colorectal Cancer
5.4 Future Trends
5.4.1 Artificial Intelligence in Colonoscopy
5.5 Impact Analysis
6. Colorectal Cancer Diagnostics Market – North America Analysis
6.1 North America Colorectal Cancer Diagnostics Market Revenue Forecast and Analysis
6.2 North America Colorectal Cancer Diagnostics Market, By Geography – Forecast and Analysis
7. North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 – by Modality
7.1 Overview
7.2 North America Colorectal Cancer Diagnostics Market Revenue Share, by Modality 2022 & 2028 (%)
7.3 Stool Based Tests
7.3.1 Overview
7.3.2 Stool Based Tests: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.3.3 Faecal Immunochemical Test (FIT)
7.3.3.1 Overview
7.3.3.2 Faecal Immunochemical Test (FIT): North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.3.4 Guaiac-based Faecal Occult Blood Test (gFOBT)
7.3.4.1 Overview
7.3.4.2 Guaiac-based Faecal Occult Blood Test (gFOBT): North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.3.5 Stool DNA Test
7.3.5.1 Overview
7.3.5.2 Stool DNA Test: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Imaging Tests
7.4.1 Overview
7.4.2 Imaging Tests: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4.3 Colonoscopy
7.4.3.1 Overview
7.4.3.2 Colonoscopy: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4.4 CT Colonography
7.4.4.1 Overview
7.4.4.2 CT Colonography: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4.5 Flexible Sigmoidoscopy
7.4.5.1 Overview
7.4.5.2 Flexible Sigmoidoscopy: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4.6 Capsule Endoscopy
7.4.6.1 Overview
7.4.6.2 Capsule Endoscopy: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4.7 Others
7.4.7.1 Overview
7.4.7.2 Others: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8. North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 – by End User
8.1 Overview
8.2 North America Colorectal Cancer Diagnostics Market Revenue Share, by End User 2022 & 2028 (%)
8.3 Hospitals
8.3.1 Overview
8.3.2 Hospitals: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Diagnostic Laboratories
8.4.1 Overview
8.4.2 Diagnostic Laboratories: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Cancer Research Institutes
8.5.1 Overview
8.5.2 Cancer Research Institutes: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9. North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 – Country Analysis
9.1 Overview
9.1.1.1 US: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.1.1 Overview
9.1.1.1.2 US: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.1.3 US: Colorectal Cancer Diagnostics Market, by Modality, 2020–2028 (US$ Million)
9.1.1.1.3.1 US: Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality, 2020–2028 (US$ Million)
9.1.1.1.3.2 US: Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality, 2020–2028 (US$ Million)
9.1.1.1.4 US: Colorectal Cancer Diagnostics Market, by End User, 2020–2028 (US$ Million)
9.1.1.2 Canada: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.2.1 Overview
9.1.1.2.2 Canada: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.2.3 Canada: Colorectal Cancer Diagnostics Market, by Modality, 2020–2028 (US$ Million)
9.1.1.2.3.1 Canada: Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality, 2020–2028 (US$ Million)
9.1.1.2.3.2 Canada: Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality, 2020–2028 (US$ Million)
9.1.1.2.4 Canada: Colorectal Cancer Diagnostics Market, by End User, 2020–2028 (US$ Million)
9.1.1.3 Mexico: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.3.1 Overview
9.1.1.3.2 Mexico: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.3.3 Mexico: Colorectal Cancer Diagnostics Market, by Modality, 2020–2028 (US$ Million)
9.1.1.3.3.1 Mexico: Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality, 2020–2028 (US$ Million)
9.1.1.3.3.2 Mexico: Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality, 2020–2028 (US$ Million)
9.1.1.3.4 Mexico: Colorectal Cancer Diagnostics Market, by End User, 2020–2028 (US$ Million)
10. North America Colorectal Cancer Diagnostics Market–Industry Landscape
10.1 Overview
10.2 Inorganic Growth Strategies
10.2.1 Overview
10.3 Organic Growth Strategies
10.3.1 Overview
11. Company Profiles
11.1 Medtronic Plc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Illumina Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Clinical Genomics Technologies Pty Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 EDP Biotech Corp
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Epigenomics AG
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 F. Hoffmann-La Roche Ltd
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Quest Diagnostics Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Siemens Healthineers AG
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Bruker Corp
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Eiken Chemical Co., Ltd.
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About Research Team
12.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Colorectal Cancer Diagnostics Market –Revenue and Forecast to 2028 (US$ Million)
Table 2. US Colorectal Cancer Diagnostics Market, by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 3. US Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 4. US Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 5. US Colorectal Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 6. Canada Colorectal Cancer Diagnostics Market, by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 7. Canada Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 8. Canada Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 9. Canada Colorectal Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 10. Mexico Colorectal Cancer Diagnostics Market, by Modality – Revenue and Forecast to 2028 (US$ Million)
Table 11. Mexico Colorectal Cancer Diagnostics Market, For Imaging Tests by Modality– Revenue and Forecast to 2028 (US$ Million)
Table 12. Mexico Colorectal Cancer Diagnostics Market, For Stool Based Tests by Modality– Revenue and Forecast to 2028 (US$ Million)
Table 13. Mexico Colorectal Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 14. Recent Inorganic Growth Strategies in the North America colorectal cancer diagnostics market
Table 15. Recent Organic Growth Strategies in the North America colorectal cancer diagnostics market
Table 16. Glossary of Terms
LIST OF FIGURES
Figure 1. North America Colorectal Cancer Diagnostics Market Segmentation
Figure 2. North America Colorectal Cancer Diagnostics Market, by Country
Figure 3. North America Colorectal Cancer Diagnostics Market Overview
Figure 4. Imaging Tests Segment Held Largest Share of Modality Segment in North America Colorectal Cancer Diagnostics Market
Figure 5. US Expected to Show Remarkable Growth During Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. North America Colorectal Cancer Diagnostics Market Impact Analysis of Driver and Restraints
Figure 9. North America Colorectal Cancer Diagnostics Market – Revenue Forecast and Analysis – 2020- 2028
Figure 10. North America Colorectal Cancer Diagnostics Market Revenue Share, by Modality 2022 & 2028 (%)
Figure 11. Stool Based Tests: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Faecal Immunochemical Test (FIT): North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Guaiac-based Faecal Occult Blood Test (gFOBT): North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Stool DNA Test: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Imaging Tests: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Colonoscopy: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. CT Colonography: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Flexible Sigmoidoscopy: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Capsule Endoscopy: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Others: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. North America Colorectal Cancer Diagnostics Market Revenue Share, by End User 2022 & 2028 (%)
Figure 22. Hospitals: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Diagnostic Laboratories: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Cancer Research Institutes: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Others: North America Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. North America: Colorectal Cancer Diagnostics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 27. North America: Colorectal Cancer Diagnostics Market, by Country, 2022 & 2028 (%)
Figure 28. US: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Canada: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Mexico: Colorectal Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
The List of Companies – Colorectal Cancer Diagnostics Market
o Bruker Corp
o Clinical Genomics Technologies Pty Ltd
o EDP Biotech Corp
o Eiken Chemical Co., Ltd.
o Epigenomics AG
o F. Hoffmann-La Roche Ltd
o Illumina Inc
o Medtronic Plc
o Quest Diagnostics Inc
o Siemens Healthineers AG
You must be logged in to post a review.
Reviews
There are no reviews yet.